« Return to News | R&D Trends

Evotec partners with Roche in $820 million Alzheimer’s deal

Tuesday, September 6, 2011 01:10 PM

Evotec has signed a new agreement with partner Roche to develop a compound with potential in Alzheimer's disease, replacing an antidepressant program which was dropped in May, according to PharmaTimes.

The German biotechnology company said it will receive $10 million in upfront licensing fees as a result of Roche's decision to collaborate on the development of the new compound, a monoamine oxidase type B inhibitor codenamed EVT-302.

The agreement could also see Evotec receive development and milestone payments up to $820m and tiered double-digit royalties on sales should the drug candidate reach the market. Proof-of-concept clinical trials are scheduled to start next year.

Roche will fund the clinical development of EVT-302, as well as any manufacturing and commercialization costs. That is good news for Evotec, given that the antidepressant program dropped earlier this year had been the main element of its collaboration with Roche. That drug, called EVT-101, had advanced to phase II testing.

MAO-B inhibitors are thought to work in Alzheimer's disease by blocking the breakdown of neurotransmitters and interrupting the formation of reactive oxygen species (ROS) involved in the inflammation and degeneration of neurons which are the hallmark of Alzheimer's disease.

"For these reasons, the selective MAO-B inhibitor is targeted to treat AD symptoms and potentially slow disease progression," said Evotec in a statement.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.